Biomarqueurs tumoraux circulants

Publications

Année de publication : 2013

Francois-Clement Bidard, Britta Weigelt, Jorge S Reis-Filho (2013 Oct 18)

Going with the flow: from circulating tumor cells to DNA.

Science translational medicine : 207ps14 : DOI : 10.1126/scitranslmed.3006305 En savoir plus
Résumé

Molecular analyses of circulating tumor DNA (ctDNA) in plasma from cancer patients have the potential to deliver minimally invasive diagnostic and disease-monitoring biomarkers. Drawing from experience gained through the translation of circulating tumor cell detection to clinical tests, we discuss ctDNA as a source of tumor material for biomarker development.

Replier
J-Y Pierga, F-C Bidard, C Cropet, P Tresca, F Dalenc, G Romieu, M Campone, C Mahier Aït-Oukhatar, E Le Rhun, A Gonçalves, M Leheurteur, J Dômont, M Gutierrez, H Curé, J-M Ferrero, C Labbe-Devilliers, T Bachelot (2013 Sep 10)

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO : 2999-3004 : DOI : 10.1093/annonc/mdt348 En savoir plus
Résumé

Decrease of circulating tumor cells (CTC) during treatment is an independent prognostic factor in metastatic breast cancer (MBC). We specifically evaluated the impact of CTC on brain metastasis outcome.

Replier
F C Bidard, F Huguet, C Louvet, L Mineur, O Bouché, B Chibaudel, P Artru, F Desseigne, J B Bachet, C Mathiot, J Y Pierga, P Hammel (2013 May 17)

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO : 2057-61 : DOI : 10.1093/annonc/mdt176 En savoir plus
Résumé

Pancreatic carcinoma is one of the leading causes of cancer-related mortality. At the time of diagnosis, 30% of patients present with a locally advanced pancreatic carcinoma (LAPC). As circulating tumor cells (CTCs) count may be a surrogate of the cancer metastatic abilities, CTC detection rates and prognostic value were studied in a prospective cohort of LAPC patients.

Replier
Antonio Giordano, Brian L Egleston, David Hajage, Joseph Bland, Gabriel N Hortobagyi, James M Reuben, Jean-Yves Pierga, Massimo Cristofanilli, Francois-Clement Bidard (2013 Jan 24)

Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research : 1596-602 : DOI : 10.1158/1078-0432.CCR-12-3137 En savoir plus
Résumé

Circulating tumor cells (CTC) represent a new outcome-associated biomarker independent from known prognostic factors in metastatic breast cancer (MBC). The objective here was to develop and validate nomograms that combined baseline CTC counts and the other prognostic factors to assess the outcome of individual patients starting first-line treatment for MBC.

Replier
S T Ligthart, F-C Bidard, C Decraene, T Bachelot, S Delaloge, E Brain, M Campone, P Viens, J-Y Pierga, L W M M Terstappen (2013 Jan 1)

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO : 1231-8 : DOI : 10.1093/annonc/mds625 En savoir plus
Résumé

Background Circulating tumor cells (CTCs) can provide the basis for a liquid biopsy and may guide the use of targeted therapies. We report on unbiased quantification of Her-2 protein expression of CTCs. Patients and methods Her-2 assessment of CTCs was carried out using the CellSearch(®) system in 103 metastatic (M1) and 88 non-metastatic (M0) breast-cancer patients. Expression of Her-2 on CTCs was determined by a manual review and an automated algorithm using Her-2- fluorescein isothiocyanate (FITC) fluorescence of leukocytes to determine the Her-2-expression threshold in each sample. Results Her-2 expression of CTCs varied greatly within and among patients compared with Her-2 expression of leukocytes. In M1 patients, a threshold of 75% of Her-2 positive CTCs in patients with ≥5 CTCs was set. Applying this threshold, 9% of M1 patients with Her-2-negative primary tumors had Her-2-positive CTC status and 29% of M1 patients with Her-2-positive primary tumors had Her-2-negative CTC status. No Her-2 discrepancy was observed between CTCs and primary tumors in M0 patients. Conclusions Our findings demonstrate that Her-2 expression is heterogeneous among CTCs within each patient. We show the feasibility of unbiased quantitative and reproducible assessment of treatment targets on CTCs, opening a path towards personalized treatment.

Replier